NCT00568139Active, not recruiting
Evaluation of Side Effects of Mitotane
Evaluierung Von Nebenwirkungen Einer Therapie Mit Mitotane Beim Nebennierenkarzinom- Evaluation of Side Effects of Mitotane in Adrenocortical Carcinoma
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many adverse effects are not well documented. Therefore, we are aiming at collecting data about adverse effects in patients treated with mitotane
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 400 (estimated)
- First submitted
- 4 Dec 2007
- Start date
- 1 Jan 2008
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University of Wuerzburg
- Diseases
- Childhood cancers
- NCT number
- NCT00568139
What you commit to
- Study type: Observational
- Planned participants: 400
- From 1 Jan 2008 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Adrenocortical carcinoma
- Treatment with mitotane monotherapy as first-line therapy (in adjuvant setting or advanced disease)
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University Hospital Coordinator of this site? Confirm its status | Würzburg | Germany | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.